Mounjaro Pen

Are you looking to discover Mounjaro, the groundbreaking weight loss treatment, now available in the UK. At My London Pharmacy, we're your trusted source when you're ready to take the next step in your weight loss journey. Mounjaro, an innovative GLP-1 agonist, has garnered attention for its remarkable results in clinical studies for both diabetes management and weight loss.

Update 8th September 2023:NICE committee recommends Mounjaro as new treatment option for people with type 2 diabetes

Buy Mounjaro in the UK

Mounjaro is available in the UK and can be requested online through our UK-registered online pharmacy. This prescription treatment is manufactured by Eli Lilly.

Understanding Mounjaro for Weight Loss

Mounjaro is tailored for individuals with a body mass index (BMI) over 30 or those with a BMI over 27 who have weight-related medical issues such as type 2 diabetes, high cholesterol, obstructive sleep apnoea, or high blood pressure.

How Mounjaro Works

Mounjaro features tirzepatide, an active ingredient that belongs to the GLP-1 agonist drug class. GLP-1 is a hormone that helps regulate hunger, naturally released by the intestines after meals. Mounjaro mirrors this hormone's action, curbing appetite and creating a feeling of fullness. This can lead to reduced calorie intake and significant weight loss. Combining Mounjaro with a calorie-controlled diet can enhance these effects.

How to Inject Mounjaro

https://info.mkthealthcare.com/uk-mounjaro-obesity

Is Mounjaro Right for You?

Consider Mounjaro for weight loss if you've previously attempted weight reduction through exercise and diet without success. Other GLP-1 treatment options are also available in the UK, including Wegovy, Liraglutide and Ozempic, which your clinician can discuss with you if Mounjaro isn't suitable.

Effectiveness of Mounjaro

Using Mounjaro pens to control appetite typically results in losing around 15-20% of your initial body weight upon completing the treatment.

Dosage and Administration

Mounjaro is administered once weekly using a pre-filled injection pen. It is typically injected into the abdomen, upper thigh, or upper arm, rotating injection sites each week.

Treatment is usually started at a dose of 2.5 mg once weekly for 4 weeks. This is a starting dose to help the body adjust.

After the initial 4 weeks, the dose may be gradually increased in 2.5 mg increments, based on clinical response and tolerability, up to a maximum of 15 mg once weekly.

Dose adjustments should always be guided by a clinician. Increasing the dose is not based solely on weight change, but on overall response, tolerability, and safety considerations.

Adherence and Effectiveness

Mounjaro has a long half-life of approximately 5 days, which supports its once-weekly dosing schedule. Consistent weekly administration is important to maintain stable drug levels in the body and ensure optimal treatment effectiveness.

Missed or inconsistent doses may reduce effectiveness and should be discussed with a clinician, as treatment plans may need to be reviewed.

Please note that the pen should be discarded 30 days after first use, regardless of whether it has been stored in the refrigerator or at room temperature.

Clinical Oversight

Mounjaro is classified as a prescription-only medicine used under strict clinical guidance. Our clinicians regularly review treatment progress, including any gaps in dosing based on ordering history, to ensure safe and appropriate use.

All dose changes and treatment decisions are made with patient safety as the highest priority.  

Do GLP-1 medications affect the combined oral contraceptive pill (COC)?

Yes. Data from Eli Lilly shows that tirzepatide (5 mg) can significantly reduce the absorption of combined oral contraceptives containing ethinyl estradiol and norgestimate.

Observed effects include: Cmax reduced by 55–66% (peak hormone levels), AUC reduced by 16–23% (overall exposure), Tmax delayed by 2.5–4.5 hours

These changes are thought to be due to delayed gastric emptying.

What is the recommended action for contraception?

Patients using combined oral contraceptives should:

Switch to a non-oral contraceptive method, OR use a barrier method (e.g. condoms) for:

The first 4 weeks after starting tirzepatide AND for 4 weeks after each dose increase

Exploring Alternatives

While Mounjaro presents an innovative approach to weight loss, it's essential to remember that adopting a healthy diet and increasing physical activity are the preferred and safest ways to lose weight. The NHS offers a 12-week weight loss plan, providing guidance on exercise and dietary improvements.

In the UK, there are alternative GLP-1 drugs, such as Wegovy, Saxenda, and Ozempic. For those who prefer non-injectable options, traditional weight loss pills like Orlistat are available.

Summary

• Mechanism: Appetite suppression
• Effectiveness: 15-20% average body weight loss
• Common Side Effects: Fatigue, dizziness, insomnia, digestive issues
• Cautions: Inappropriate for individuals with certain medical conditions; potential drug interactions

When considering Mounjaro for weight loss, consult with your healthcare provider for personalised guidance.

References:

1. National Institute for Health and Care Excellence (NICE) Guidelines.
2. Clinical Trials and Studies on Tirzepatide (Mounjaro).
3. UK Diabetes Organisations and Resources.
4. Tirzepatide: A Novel GLP-1 Agonist for Type 2 Diabetes and Beyond (Clinical Study).
5. Tirzepatide for Type 2 Diabetes Mellitus: A Comprehensive Review (Clinical Study).
6. Eli Lilly Official Website.
7. NICE Recommends Mounjaro (Tirzepatide) for Type 2 Diabetes

Mounjaro and Sleep Apnea

Clinical trials (SURMOUNT-OSA) have shown that tirzepatide (Mounjaro/Zepbound) can significantly reduce the severity of obstructive sleep apnoea (OSA) in adults with obesity. The study demonstrated meaningful improvements in the apnoea–hypopnoea index (AHI), with reductions of around 55–63% compared with minimal change on placebo, alongside substantial weight loss of approximately 18–20%. These benefits are thought to be primarily driven by weight reduction and improved metabolic function. While tirzepatide may help improve symptoms such as snoring, daytime fatigue, and breathing interruptions during sleep, it is not a replacement for standard OSA treatments such as CPAP, which should continue to be used where prescribed.

Ref: Tirzepatide Shows Significant Reduction in Severity of Obstructive Sleep Apnea in Patients with Obesity | Applied Clinical Trials Online

Mounjaro (Tirzepatide) Multi-Dose Treatment Packs – Important Information

Mounjaro can cause side effects, particularly when starting treatment or increasing the dose. Common side effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, indigestion, reduced appetite, and bloating.

Not all patients tolerate dose increases at the same rate. Some patients may need to remain on a lower dose for longer than planned, delay dose escalation, or discontinue treatment following clinical review.

If you are new to Mounjaro or have not previously completed dose escalation successfully, please carefully consider whether purchasing a treatment pack containing multiple strengths (2.5 mg, 5 mg, and 7.5 mg) is appropriate for you.

As prescription medicines cannot be reused or resold once supplied, all dispensed medicines are non-returnable and non-refundable except where required by law. If your treatment needs to be adjusted due to side effects or tolerability issues, unused medication cannot be returned for a refund.